Cost-Effectiveness Of Idelalisib In Combination With Rituximab For The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) In Portugal
Nov 1, 2015, 00:00 AM
10.1016/j.jval.2015.09.1197
https://www.valueinhealthjournal.com/article/S1098-3015(15)03273-8/fulltext
Section Title :
Research Podium Presentations - Session 1 and Session 2
Section Order :
696
First Page :
A461
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03273-8&doi=10.1016/j.jval.2015.09.1197